Vnitr Lek 2008, 54(5):499-507

Diabetes mellitus, hypertension and kidney

V. Monhart
Interní klinika 1. lékařské fakulty UK a ÚVN Praha, přednosta prof. MUDr. Miroslav Zavoral, Ph.D.

The correlations co-exist among diabetes mellitus, hypertension and the kidney. Renal injury will develop in 35% type 1 and type 2 diabetes mellitus patients. Diabetic nephropathy is the key factor for the occurence of hypertension in type 1 diabetes mellitus. In case of type 2 diabetes mellitus with prevalent essencial hypertension the diabetic nephropathy is supporting factor for the development of hypertension. Untreated or inadequately treated hypertension accelerates the progression of diabetic renal impairment. The presence of diabetes mellitus as well as hypertension or proteinuria is significant cardiovascular risk factor. The goal of treatment with angiotensin converting enzyme inhibitors or AT1 receptor of angiotensin II blockers is both slowing-down of renal injury progression and reduction in risk of cardiovascular complications.

Keywords: diabetes mellitus; arterial hypertension; diabetic nephropathy; renoprotection; ACE inhibitors; AT1 blockers

Received: March 31, 2008; Published: May 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Monhart V. Diabetes mellitus, hypertension and kidney. Vnitr Lek. 2008;54(5):499-507.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Svačina Š. Hypertenze při obezitě a diabetu. Praha: Triton 2007.
    2. Cífková R. Léčba hypertenze u pacientů s diabetes mellitus ve světle posledních evropských doporučení. Remedia 2004; 14: 133-141.
    3. Škrha J. Arteriální hypertenze u diabetiků v ČR: výsledky studie. In: Widimský J et al. Arteriální hypertenze - současné klinické trendy. V. sympozium. Praha: Triton 2007: 43-48.
    4. Parving HH. Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy, and endothelial permeability in diabetes mellitus. Diabetes Care 1991; 14: 260-269. Go to original source... Go to PubMed...
    5. Tesař V. Hypertenze u diabetické nefropatie. In: Rychlík I, Tesař V et al. Onemocnění ledvin u diabetes mellitus. Horizonty diabetologie. Díl 2. Praha: Tigis 2005: 150-161.
    6. Rychlík I, Tesař V et al. Onemocnění ledvin u diabetes mellitus. Horizonty diabetologie. Díl 2. Praha: Tigis 2005.
    7. De Mast Q, Beutler JJ. Prevalence of atherosclerotic renal artery stenosis: a metaanalysis of 33 studies and 13,591 patients. J Hypertens 2005; 23(Suppl 2): S333.
    8. Monhart V. Ischemická nefropatie u diabetiků. In: Rychlík I, Tesař V et al. Onemocnění ledvin u diabetes mellitus. Horizonty diabetologie. Díl 2. Praha: Tigis 2005: 242-254.
    9. Dusilová Sulková S, Rychlík I. Přístup nefrologa k diabetikovi s poškozením ledvin. In: Dusilová Sulková S, Šmahelová A. Multidisciplinární přístup k diabetikovi s onemocněním ledvin. Praha: Tigis 2007: 43-52.
    10. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187. Go to original source... Go to PubMed...
    11. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49(Suppl 2): S1-S179.
    12. Widimský J jr, Cífková R, Špinar J et al (za Českou společnost pro hypertenzi). Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi. Cor et Vasa 2008; 50: K005-K020.
    13. Marshall SM. Clinical features and management of diabetic nephropathy. In: Textbook of Diabetes. 3rd ed. Oxford: Blackwell Science 2006: 53.1-53.22.
    14. Rušavý Z. Diabetická nefropatie. Akt Nefrol 2002; 8: 77-81.
    15. Bakker A. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999; 22: 307-313. Go to original source... Go to PubMed...
    16. Allen T, Cao Z, Youssef S et al. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes 1997; 46: 1612-1618. Go to original source... Go to PubMed...
    17. Bakris GL, Weir MR, De Quatro V et al. Effects of an ACE inhibitors/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283-1289. Go to original source... Go to PubMed...
    18. Perušičová J, Rosolová H, Kvapil M. Mikroalbuminurie. In: Trendy soudobé nefrologie. Praha: Galén 1999: 121-135.
    19. Chatuverdi N, Bandinelli S, Mangili R et al. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 2001; 60: 219-227. Go to original source... Go to PubMed...
    20. Mogensen CE. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes 1997; 46(Suppl 2): S104-S111. Go to original source... Go to PubMed...
    21. UKPDS Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications on patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. Go to original source...
    22. Miyata T, van Ypersele de Strihou Ch. Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering. Nephrol Dial Transplant 2006; 21: 846-849. Go to original source... Go to PubMed...
    23. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713. Go to original source... Go to PubMed...
    24. Villarosa IP, Bakris GL. Antihypertensive therapy in type 2 diabetes with neprohropathy. In: Ritz E, Rychlík I (eds). Nepropathy in type 2 diabetes. Oxford: Oxford University Press 1999: 111-136. Go to original source...
    25. Kasiske BL, Kalil RS, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-138. Go to original source... Go to PubMed...
    26. Monhart V. Hypertenze a ledviny. Praha: Triton 2007.
    27. The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792. Go to original source...
    28. Viberti G, Mogensen CE, Groop LC et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271: 275-279. Go to original source...
    29. Katayama S, Kikkawa R, Isogai S et al. Effect of captopril or imidapril on the progression of diabetic nepropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diab Res Clin Pract 2002; 55: 113-121. Go to original source... Go to PubMed...
    30. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462. Go to original source... Go to PubMed...
    31. Ravid M, Brosh D, Levi Z et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 128: 982-988. Go to original source... Go to PubMed...
    32. Ruggenenti P, Fassi A, Parvano Ilieva A et al (for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)). Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951. Go to original source... Go to PubMed...
    33. Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-581. Go to original source... Go to PubMed...
    34. Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 1995; 47: 907-910. Go to original source... Go to PubMed...
    35. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259. Go to original source...
    36. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961. Go to original source... Go to PubMed...
    37. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan of the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878. Go to original source... Go to PubMed...
    38. Viberti G, Wheeldon NM (for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators). Microalbuminuria reduction with valsartran in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002; 106: 672-678. Go to original source... Go to PubMed...
    39. Brenner BM, Coper ME, deZeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869. Go to original source... Go to PubMed...
    40. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 851-860. Go to original source... Go to PubMed...
    41. Galle J, Quispe Bravo S, Wanner C. Antiproteinuric effects of telmisartan versus valsartan in patients with type 2 diabetes and overt nephropathy. Diabet Med 2006; 23(Suppl 4): 92-93.
    42. Burgess E, Bakris G, Weir M et al. Comparative long term effects of two AT1 receptor blockers on proteinuria in patients with type-2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial. J Hypertens 2007; 25(Suppl 2): S276-S277.
    43. Mogensen CE, Neldan S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Brit Med J 2000; 321: 1440-1444. Go to original source... Go to PubMed...
    44. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12. Go to original source... Go to PubMed...
    45. De Zeeuw D, Hillege HL, de Jong PE. The kidney, a cardiovascular risk marker and a new target for therapy. Kidney Int 2005; 68(Suppl 98): 25-29. Go to original source... Go to PubMed...
    46. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: Estimations for the year 2000 and projection for 2030. Diabetes Care 2004; 27: 1047-1053. Go to original source... Go to PubMed...
    47. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223. Go to original source... Go to PubMed...
    48. National Kidney Foundation. K/DOQI Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease: executive summary. Am J Kidney Dis 2004; 43: S14-S33. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.